Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Everolimus may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow
to the tumor. It is not yet known whether giving everolimus together with trastuzumab is more
effective than giving trastuzumab alone in treating women with breast cancer.
PURPOSE: This randomized phase II trial is studying trastuzumab and everolimus to see how
well they work compared to trastuzumab alone before surgery in treating patients with breast
cancer that can be removed by surgery.